Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

966
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
966
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

4.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

462
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
462
Disorders of Hemostasis01:24

Disorders of Hemostasis

690
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
690
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

602
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
602
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

3.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-read sequencing reveals SVA insertion in AP3B1 causing Hermansky-Pudlak syndrome 2.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Beyond Conventional Hemostasis Testing: The Diagnostic Impact of Genetic Analysis in inherited Mild Bleeding Disorders.

Hamostaseologie·2026
Same author

Lower resting-state EEG mean eigenvector centrality is associated with higher math anxiety.

Frontiers in human neuroscience·2026
Same author

Peripheral Blood Morphology as a Clue to 22q11.2 Deletion Syndrome.

EJHaem·2026
Same author

Navigating the Diagnostic and Clinical Spectrum of Thrombocytopenia and Thrombocytopathy: Lessons from a Case Series.

Hamostaseologie·2026
Same author

Free-Energy Landscapes of HBV Hexamer Closure Reveal Key Structural Features of the Transition.

Journal of chemical theory and computation·2026

Related Experiment Video

Updated: May 30, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

759

The Diagnostic Assessment of Platelet Function Defects - Part 2: Update on Platelet Disorders.

Karina Althaus1,2, Gero Hoepner2,3, Barbara Zieger4

  • 1Medical Faculty of Tübingen, Institute for Clinical and Experimental Transfusion Medicine, Tübingen, Germany.

Hamostaseologie
|January 27, 2025
PubMed
Summary

Inherited platelet function disorders (iPFDs) are rare, often misdiagnosed, and require precise diagnosis. Understanding their genetics, presentation, and lab analysis is crucial for effective management and avoiding complications.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

185
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Related Experiment Videos

Last Updated: May 30, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

759
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

185
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Congenital platelet disorders, including inherited platelet function disorders (iPFDs), are rare conditions impacting platelet function.
  • These disorders can involve surface receptors, platelet granules, signal transduction, or procoagulant activity, and are often misdiagnosed, especially when associated with thrombocytopenia.

Purpose of the Study:

  • To review the genetics, clinical presentation, and laboratory analysis of iPFDs.
  • To highlight the importance of accurate diagnosis for patient management, particularly in perioperative settings and in cases of potential isoimmunization.

Main Methods:

  • Review of existing literature on iPFDs.
  • Focus on genetic, phenotypic, and functional analyses of platelet defects.
  • Discussion of clinical implications and diagnostic challenges.

Main Results:

  • iPFDs present with variable bleeding tendencies and can be mistaken for immune thrombocytopenia.
  • Platelet receptor deficiencies (e.g., Bernard-Soulier syndrome, Glanzmann thrombasthenia) carry risks of bleeding and isoimmunization.
  • Platelet granule disorders involve quantitative/qualitative defects or release issues, potentially affecting signaling pathways.

Conclusions:

  • Accurate diagnosis of iPFDs through phenotyping, functional assays, and genotyping is essential for appropriate patient care.
  • Understanding the specific defect is critical for managing bleeding risk, perioperative care, and potential complications like isoimmunization.
  • This review emphasizes the integration of genetic and functional data for comprehensive iPFD assessment.